Endothelial Biomarkers Are Superior to Classic Inflammatory Biomarkers in Community-Acquired Pneumonia.

Autores de IIS La Fe

• Paula González Jiménez

  Autor

• Mónica Piqueras Rodríguez

  Autor

• Ana Latorre Garcia

  Autor

• Jordi Tortosa Carreres

  Autor

• Noé Mengot Ruiz

  Autor

• Ricardo Miguel Alonso Díaz

  Autor

• Soledad Reyes Calzada

  Autor

• Isabel Emilia Amara Elori

  Autor

• 

  Luis Vicente Martínez Dolz

  Autor

• Antonio Moscardó Martínez

  Autor

• Rosario Menéndez Villanueva

  Autor

• Raúl Méndez Ocaña

  Autor

Grupos

• Grupo de Investigación Clínica y Traslacional en Cardiología

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

• Infecciones Respiratorias

Abstract

Background: Complications in community-acquired pneumonia (CAP), including cardiovascular events (CVE), can occur during an acute episode and in the long term. We aimed to analyse the role of endothelial damage biomarkers (C-terminal endothelin-1 precursor fragment [CT-proET-1] and mid-regional pro-adrenomedullin [MR-proADM]), in contrast to classic inflammation markers (C Reactive Protein [CRP] and procalcitonin [PCT]) in patients admitted for CAP and their relationship with ICU admission, CVE and mortality in the short and long term; Methods: Biomarkers were analysed in 515 patients with CAP at day 1, 285 at day 5 and 280 at day 30. Traditional inflammatory biomarkers and endothelial damage biomarkers were measured. ICU admission, CVE and mortality (in-hospital and 1-year follow-up) were assessed using receiver operating characteristic (ROC) curve analysis and univariate logistic regression. Results: A statistically significant association was observed between initial, raised CT-proET-1 and MR-proADM levels, the need for ICU admission and the development of in-hospital CVE or in-hospital mortality. Both endothelial markers maintained a strong association at day 30 with 1-year follow-up CVE. At day 1, CRP and PCT were only associated with ICU admission. On day 30, there was no association between inflammatory markers and long-term CVE or death. The odds ratio (OR) and area under the curve (AUC) of endothelial biomarkers were superior to those of classic biomarkers for all outcomes considered. Conclusions: Endothelial biomarkers are better indicators than classic ones in predicting worse outcomes in both the short and long term, especially CVE. MR-proADM is the best biomarker for predicting complications in CAP.

Keywords

• CAP; CT-proET-1; MR-proADM; cardiovascular events; inflammatory biomarkers